title: Role of central histaminergic system in lorazepam withdrawal syndrome in rats.
abstract: Effects of histaminergic agonists and antagonists were investigated on withdrawal signs in lorazepam-dependent rats. Physical dependence was developed by giving lorazepam admixed with the food in the following dose schedule (in mg/kg given daily x days): 10 x 4, 20 x 4, 40 x 4, 80 x 4, and 120 x 7. The parameters observed during the periods of administration of lorazepam and after its withdrawal were spontaneous locomotor activity (SLA), reaction time to pain, foot shock aggression (FSA), and audiogenic seizures. During the withdrawal period, the rats were divided into groups of 10 each. Control-withdrawal group did not receive any drug. The drugs (in mg/kg administered intramuscularly)--L-histidine (50), histamine-N-methyl (2), promethazine (10), pheniramine (10), astemizole (10), and thioperamide (1)--were given separately in other groups daily during the withdrawal period. The withdrawal signs in control group were hyperkinesia, hyperaggression, and audiogenic seizures. L-Histidine, precursor of histamine, and thioperamide, antagonist of H3 receptor, potentiated hyperkinesia, hyperaggression, and audiogenic seizures. Histamine-N-methyl, agonist of H3 receptor, and H1 receptor antagonists, promethazine and pheniramine, blocked all the withdrawal signs. Astemizole, a peripheral antagonist of H1 receptor, could not affect any withdrawal sign. It may be concluded that histamine H1 receptors are facilitatory and H3 receptors are inhibitory for benzodiazepine (BZD) withdrawal syndrome.
authors.affiliation: Division of Pharmacology, Central Drug Research Institute, Lucknow, India. root@csdri.ren.nic.in
authors.forename: C
authors.initials: C
authors.lastname: Nath
authors.forename: M B
authors.initials: MB
authors.lastname: Gupta
mesh_terms: D000161:Acoustic Stimulation; D000818:Animals; D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D020195:Epilepsy, Reflex / Q000139:chemically induced; D006632:Histamine / Q000502:physiology; D017442:Histamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D008140:Lorazepam / Q000009:adverse effects*; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D011969:Receptors, Histamine H1 / Q000502:physiology; D018100:Receptors, Histamine H3 / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy
chemical_list: D014151:Anti-Anxiety Agents; D017442:Histamine Agonists; D006633:Histamine Antagonists; D011969:Receptors, Histamine H1; D018100:Receptors, Histamine H3; D006632:Histamine; D008140:Lorazepam